In vitro affinity maturation of HuCAL antibodies: complementarity determining region exchange and RapMAT technology.
Monoclonal antibodies gain ever-increasing importance in the treatment of human diseases across a broad range of indications. Diverse technologies currently exist, which are used to generate recombinant therapeutic antibodies that are basically indistinguishable from naturally occurring human immunoglobulins. We describe how human combinatorial antibody libraries are used together with unique optimization techniques to produce such therapeutically relevant proteins, for instance in the areas of oncology and inflammation.
Prassler
Josef
J
MorphoSys AG, Lena-Christ-Str. 48, 82152 Martinsried/Planegg, Germany.
Steidl
Stefan
S
Urlinger
Stefanie
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D000915:Antibody Affinity / Q000235:genetics; D020650:Combinatorial Chemistry Techniques; D022801:Complementarity Determining Regions / Q000235:genetics; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D051379:Mice; D019151:Peptide Library; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000276:immunology
D000911:Antibodies, Monoclonal; D022801:Complementarity Determining Regions; D019151:Peptide Library; D011994:Recombinant Proteins; D019715:Tissue Inhibitor of Metalloproteinase-1